HK1210598A1 - Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation - Google Patents

Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation Download PDF

Info

Publication number
HK1210598A1
HK1210598A1 HK15111382.6A HK15111382A HK1210598A1 HK 1210598 A1 HK1210598 A1 HK 1210598A1 HK 15111382 A HK15111382 A HK 15111382A HK 1210598 A1 HK1210598 A1 HK 1210598A1
Authority
HK
Hong Kong
Prior art keywords
protein aggregation
tri
inhibitors
heteroaryl derivatives
methods
Prior art date
Application number
HK15111382.6A
Other languages
English (en)
Chinese (zh)
Inventor
Wolfgang Wrasidlo
Original Assignee
Neuropore Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies, Inc. filed Critical Neuropore Therapies, Inc.
Publication of HK1210598A1 publication Critical patent/HK1210598A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15111382.6A 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation HK1210598A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672239P 2012-07-16 2012-07-16
US201261672239P 2012-07-16
PCT/US2013/050719 WO2014014937A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
HK1210598A1 true HK1210598A1 (en) 2016-04-29

Family

ID=49949212

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111382.6A HK1210598A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Country Status (15)

Country Link
US (1) US9284309B2 (enExample)
EP (1) EP2872143B1 (enExample)
JP (1) JP2015522617A (enExample)
KR (1) KR20150031481A (enExample)
CN (1) CN104703604A (enExample)
AU (1) AU2013290361A1 (enExample)
BR (1) BR112015001096A2 (enExample)
CA (1) CA2877983A1 (enExample)
ES (1) ES2661394T3 (enExample)
HK (1) HK1210598A1 (enExample)
IL (1) IL236712A0 (enExample)
IN (1) IN2015DN01171A (enExample)
MX (1) MX2015000618A (enExample)
RU (1) RU2015104962A (enExample)
WO (1) WO2014014937A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809440T4 (tr) 2014-01-29 2018-07-23 Ucb Biopharma Sprl Protein agregasyonunun inhibitörleri olarak heteroaril amidler.
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
KR20190111080A (ko) * 2017-01-26 2019-10-01 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 비스-헤테로아릴 유도체
ES2884145T3 (es) 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas
EA201991753A1 (ru) 2017-01-26 2020-01-14 Юсб Байофарма Спрл Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
US20190382346A1 (en) 2017-02-28 2019-12-19 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂
WO2025223458A1 (zh) * 2024-04-23 2025-10-30 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056993A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
ATE335737T1 (de) 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
WO2004014905A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
ES2644724T3 (es) 2009-04-30 2017-11-30 Glaxo Group Limited Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
WO2011146748A1 (en) * 2010-05-21 2011-11-24 New York University Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase

Also Published As

Publication number Publication date
US20150183776A1 (en) 2015-07-02
BR112015001096A2 (pt) 2017-06-27
AU2013290361A1 (en) 2015-02-05
CA2877983A1 (en) 2014-01-23
EP2872143B1 (en) 2017-12-13
ES2661394T3 (es) 2018-03-28
IN2015DN01171A (enExample) 2015-06-26
EP2872143A4 (en) 2015-12-02
WO2014014937A1 (en) 2014-01-23
KR20150031481A (ko) 2015-03-24
US9284309B2 (en) 2016-03-15
RU2015104962A (ru) 2016-09-10
MX2015000618A (es) 2015-04-10
IL236712A0 (en) 2015-02-26
EP2872143A1 (en) 2015-05-20
CN104703604A (zh) 2015-06-10
JP2015522617A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
HK1210598A1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
WO2015116663A8 (en) Heteroaryl amides as inhibitors of protein aggregation
WO2015004533A3 (en) Novel substituted bicyclic compounds as bromodomain inhibitors
HK1243410A1 (zh) 新型化合物
HK1220442A1 (zh) Ido抑制剂
WO2015108490A3 (en) Heteroaryl alkyne derivatives and uses thereof
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
MX2016004114A (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1.
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EP3103802A4 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
HK1202452A1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
MX2019007054A (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas.
EP3501524A4 (en) USE OF PHYTOSPHINGOSINE-1-PHOSPHATE OR A DERIVATIVE THEREOF AS AN IMMUNE ACTIVATOR OR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DEMENTIA
JO3483B1 (ar) 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي
WO2013155465A8 (en) Substituted xanthine derivatives
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
EP3121167A4 (en) Compound binding to pparg but not acting as promoter and pharmaceutical composition for treating pparg-related diseases containing same as active ingredient
MX2017013453A (es) Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica.